229 related articles for article (PubMed ID: 35966591)
1. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.
Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S
Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591
[No Abstract] [Full Text] [Related]
2. USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells.
Karapurkar JK; Colaco JC; Suresh B; Tyagi A; Woo SH; Jo WJ; Ko N; Singh V; Hong SH; Oh SJ; Kim KS; Ramakrishna S
Cell Mol Life Sci; 2024 Mar; 81(1):145. PubMed ID: 38498222
[TBL] [Abstract][Full Text] [Related]
3. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.
Pan C; Chun J; Li D; Boese AC; Li J; Kang J; Umano A; Jiang Y; Song L; Magliocca KR; Chen ZG; Saba NF; Shin DM; Owonikoko TK; Lonial S; Jin L; Kang S
J Clin Invest; 2019 Oct; 129(10):4110-4123. PubMed ID: 31449053
[TBL] [Abstract][Full Text] [Related]
4. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang HB; Song L; Wang D; Zhang G; Fan J; Boggon TJ; Zhou L; Kowalski J; Qu CK; Steuer CE; Chen GZ; Saba NF; Boise LH; Owonikoko TK; Khuri FR; Magliocca KR; Shin DM; Lonial S; Kang S
Cancer Cell; 2018 Aug; 34(2):315-330.e7. PubMed ID: 30033091
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis.
Karapurkar JK; Kim MS; Colaco JC; Suresh B; Sarodaya N; Kim DH; Park CH; Hong SH; Kim KS; Ramakrishna S
J Exp Clin Cancer Res; 2023 May; 42(1):121. PubMed ID: 37170124
[TBL] [Abstract][Full Text] [Related]
6. USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy.
Raimondi M; Cesselli D; Di Loreto C; La Marra F; Schneider C; Demarchi F
Autophagy; 2019 Apr; 15(4):613-630. PubMed ID: 30335599
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.
Pan C; Kang J; Hwang JS; Li J; Boese AC; Wang X; Yang L; Boggon TJ; Chen GZ; Saba NF; Shin DM; Magliocca KR; Jin L; Kang S
Nat Commun; 2021 Aug; 12(1):4960. PubMed ID: 34400618
[TBL] [Abstract][Full Text] [Related]
8. Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance.
Sourisseau T; Helissey C; Lefebvre C; Ponsonnailles F; Malka-Mahieu H; Olaussen KA; André F; Vagner S; Soria JC
Cell Cycle; 2016; 15(2):295-302. PubMed ID: 26825230
[TBL] [Abstract][Full Text] [Related]
9. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells.
Liao Y; Shao Z; Liu Y; Xia X; Deng Y; Yu C; Sun W; Kong W; He X; Liu F; Guo Z; Chen G; Tang D; Gan H; Liu J; Huang H
J Exp Clin Cancer Res; 2021 Jun; 40(1):201. PubMed ID: 34154657
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer.
Simoneau A; Engel JL; Bandi M; Lazarides K; Liu S; Meier SR; Choi AH; Zhang H; Shen B; Martires L; Gotur D; Pham TV; Li F; Gu L; Gong S; Zhang M; Wilker E; Pan X; Whittington DA; Throner S; Maxwell JP; Chen Y; Yu Y; Huang A; Andersen JN; Feng T
Mol Cancer Ther; 2023 Feb; 22(2):215-226. PubMed ID: 36228090
[TBL] [Abstract][Full Text] [Related]
11. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.
Chandrasekaran AP; Kaushal K; Park CH; Kim KS; Ramakrishna S
Theranostics; 2021; 11(20):9752-9771. PubMed ID: 34815782
[No Abstract] [Full Text] [Related]
12. USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses.
Yu Z; Song H; Jia M; Zhang J; Wang W; Li Q; Zhang L; Zhao W
J Exp Med; 2017 Dec; 214(12):3553-3563. PubMed ID: 29138248
[TBL] [Abstract][Full Text] [Related]
13. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells.
Chen J; Dexheimer TS; Ai Y; Liang Q; Villamil MA; Inglese J; Maloney DJ; Jadhav A; Simeonov A; Zhuang Z
Chem Biol; 2011 Nov; 18(11):1390-400. PubMed ID: 22118673
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and miR-216a-5p-mediated upregulation of DR5.
Woo SM; Kim S; Seo SU; Kim S; Park JW; Kim G; Choi YR; Hur K; Kwon TK
Cell Death Dis; 2022 Sep; 13(9):821. PubMed ID: 36153316
[TBL] [Abstract][Full Text] [Related]
15. Structure-function analysis of USP1: insights into the role of Ser313 phosphorylation site and the effect of cancer-associated mutations on autocleavage.
Olazabal-Herrero A; García-Santisteban I; Rodríguez JA
Mol Cancer; 2015 Feb; 14(1):33. PubMed ID: 25744535
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the 'Fingers' subdomain of the deubiquitinase USP1 modulate its function and activity.
Olazabal-Herrero A; García-Santisteban I; Rodríguez JA
FEBS J; 2016 Mar; 283(5):929-46. PubMed ID: 26758085
[TBL] [Abstract][Full Text] [Related]
17. Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer.
Das S; Chandrasekaran AP; Suresh B; Haq S; Kang JH; Lee SJ; Kim J; Kim J; Lee S; Kim HH; Kim KS; Ramakrishna S
Cell Death Differ; 2020 Nov; 27(11):3004-3020. PubMed ID: 32415280
[TBL] [Abstract][Full Text] [Related]
18. The role of USP1 deubiquitinase in the pathogenesis and therapy of cancer.
Antonenko S; Zavelevich M; Telegeev G
Acta Biochim Pol; 2023 Jun; 70(2):219-231. PubMed ID: 37331010
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-specific peptidase 1: assessing its role in cancer therapy.
Huang P; Wang Y; Zhang P; Li Q
Clin Exp Med; 2023 Nov; 23(7):2953-2966. PubMed ID: 37093451
[TBL] [Abstract][Full Text] [Related]
20. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
